Clinical trial NCT05324800: the Efficacy and Safety of Curcuma Longa Extract Mixture on Immune Enhancement
Official title: This Study Was a 8 Weeks, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Curcuma Longa Extract Mixture on Immune Enhancement
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Immunity
Keywords: Immunity
Curcuma Longa
Lead sponsor: Chonbuk National University Hospital
Sponsor class: OTHER
First posted: 2022-04-12
Enrollment: 100
Sex: ALL
Minimum age (years): 19
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study was conducted to investigate the efficacy and safety of Curcuma longa extract mixture on immune enhancement

Detailed description: This study was 8 weeks, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Curcuma longa extract mixture on immune enhancement

Eligibility criteria: Inclusion Criteria:

* Adult men and women over 19 and under 75 years
* After fully hearing and fully understanding this clinical trials, those who agree to voluntarily decide to participate and to comply with the notice

Exclusion Criteria:

* If screening shows that the white blood cell(WBC) is less than 3000/㎕ or more than 8000/㎕
* Those who received influenza vaccination within 2 months before first intake of intervention
* Those who have a body mass index(BMI) of less than 18.5 kg / m\^2 or greater than 35 kg / m\^2 at the screening
* Those who have a clinically significant acute or chronic cardiovascular system, endocrine system, immune system, respiratory system, liver biliary system, kidney and urinary system, neuropsychiatry, musculoskeletal system, inflammatory and hematologic and gastrointestinal disorders
* Those who take a medication or health function food that affects your promotion of immunity within 1 month prior to the screening
* Those who have received antipsychotic medication within 3 months before screening
* Those who alcoholic or drug abuse suspected
* Those who participated in other clinical trials within 3 months before screening
* Laboratory test by show the following results

  * Aspartate Transaminase(AST), Alanine Transaminase(ALT) \> Reference range 3 times upper limit
  * Serum Creatinine \> 2.0 mg/dL
* Pregnancy or breast feeding
* Those who doesn't accept the implementation of appropriate contraception of a childbearing woman
* Principal Investigator judged inappropriate for participation in study because of Laboratory test result, etc.

Primary outcomes:
measure: Changes of Natural Killer cell activity
timeFrame: baseline and 8 weeks
Secondary outcomes:
measure: Changes of Interleukin-2, Interleukin-12, Interferon-Gamma and Tumor necrosis factor-alpha
timeFrame: baseline and 8 weeks
measure: Changes of Wisconsin Upper Respiratory Symptom Survey-21(WURSS-21)
timeFrame: baseline, 4 weeks and 8 weeks
Other outcomes:
Locations:
city: Jeonju
country: Korea, Republic of
facility: Clinical Trial Center for Functional Foods Chonbuk National University Hospital
state: Jeollabuk-do
Study officials:
References: